Remove Clinical Development Remove Drug Development Remove Marketing
article thumbnail

Harnessing AI and Real-World Data: The Future of Clinical Development

PPD

The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. In a recent panel discussion at DIA Global , our experts explored how these elements are reshaping clinical research and drug discovery.

52
article thumbnail

A personal view on antibody drug development

Drug Discovery World

Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated, safe and developable bi-specific therapeutic ADC candidates to clinical development. Biological targets The choice of a biological target invariably determines the future success of a drug.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Three trends in the antibody-drug conjugate (ADC) marketĀ 

Drug Discovery World

According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Marketing 245
article thumbnail

What is the biggest barrier to rare disease drug development?

Drug Discovery World

Dr Asma Patel , Vice President of Integrated Services for Early Development at Quotient Sciences, reflects on the biggest barriers to rare disease drug development and how companies can overcome these. The post What is the biggest barrier to rare disease drug development?

article thumbnail

Free clinical trial health check to bring drugs to market faster

Drug Discovery World

Protocol amendments slow down clinical development and are extremely costly. The post Free clinical trial health check to bring drugs to market faster appeared first on Drug Discovery World (DDW). The average Phase III protocol experiences 3.3 months of implementation time.

article thumbnail

Liquid biopsy helps advance oncology drug development

Drug Target Review

Why is detecting cancers via liquid biopsy before they become visible on imaging important for drug development, not just diagnostics? We believe liquid biopsy is very helpful for oncology drug development because the reduction and clearance of circulating DNA occurs quickly before radiographic imaging is available.

article thumbnail

Navigating the challenges and opportunities of AI in drug development and personalised medicine

Drug Target Review

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. Cavlan explains that ā€œthey are brilliant at developing and bringing new drugs to market.ā€